Our group showed that pre-engagement of CD180 with anti-CD180 followed by treatment with anti-IgM in AKT-s CLL cells significantly decreases levels of p-AKT, increases p38MAPK, and increases the number of apoptotic cells (Porakishvili et al. 2015). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.